Maternal RSV Vaccine Stopped During Clinical Trials Due To Safety Concerns, FDA Approved Similar Vaccine From Different Manufacturer

According to an article published by JAMA Network, researchers for a maternal vaccine against respiratory syncytial virus (RSV) in infants stopped clinical trials because of an increased risk of preterm births.

“A vaccine given during pregnancy that prevents RSV in infants was about 66% effective at protecting against RSV-associated respiratory illness, and about 69% effective at protecting against severe disease, according to a study in the New England Journal of Medicine,” Chief Nerd wrote, citing JAMA Network.

“However, the researchers stopped the trial early because of an increased risk of preterm births. Despite the potential risks of maternal RSV vaccination, ‘it is essential to weigh this small risk against the proven benefits,’ the authors of a linked editorial wrote, adding that most of the preterm births

Continue reading